📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. (2014)

First Author: Reither K

Attributed to: Epidemiological and statistical research on health problems of developing countries: MRC Tropical Epidemiology Group funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0114602

PubMed Identifier: 25490675

Publication URI: http://europepmc.org/abstract/MED/25490675

Type: Journal Article/Review

Volume: 9

Parent Publication: PloS one

Issue: 12

ISSN: 1932-6203